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Abstract
Background: Skin malformations that resembled manifestations of Ehlers-Danlos-Syndrome were described in a
variety of domestic animals during the last century as cutis hyperelastica, hyperelastosis cutis, dermatosparaxis,
dermal/collagen dysplasia, dermal/cutaneous asthenia or Ehlers-Danlos-like syndrome/s. In 2007, the mutation
responsible for Hereditary Equine Regional Dermal Asthenia (HERDA) in Quarter Horses was discovered. Several case
reports are available for similar malformations in other breeds than Quarter Horses (Draught Horses, Arabians, and
Thoroughbreds) including four case reports for Warmblood horses. Since 2013, a genetic test for the Warmblood
Fragile Foal Syndrome Type 1 (WFFS), interrogating the causative point mutation in the equine procollagen-lysine,
2-oxoglutarate 5-dioxygenase 1 (PLOD1, or lysyl hydroxylase 1) gene, has become available. Only limited data are
available on the occurrence rate and clinical characteristics of this newly detected genetic disease in horses. In
humans mutations in this gene are associated with Ehlers-Danlos Syndrome Type VI (kyphoscoliotic form).
Case presentation: This is the first report describing the clinical and histopathological findings in a foal confirmed
to be homozygous positive for WFFS. The Warmblood filly was born with very thin, friable skin, skin lesions on the
legs and the head, and an open abdomen. These abnormalities required euthanasia just after delivery. Histologic
examination revealed abnormally thin dermis, markedly reduced amounts of dermal collagen bundles, with loosely
orientation and abnormally large spaces between deep dermal fibers.
Conclusion: WFFS is a novel genetic disease in horses and should be considered in cases of abortion, stillbirth, skin
lesions and malformations of the skin in neonatal foals. Genetic testing of suspicious cases will contribute to
evaluate the frequency of occurrence of clinical WFFS cases and its relevance for the horse population.
Keywords: PLOD1, Equine procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1, LH1, Lysyl hydroxylase 1, Ehlers-Danlos
syndrome, Dermatosparaxis, Dermal hyperfragility, Horse, Equine, Connective tissue, Hereditary
Background
A hereditary disease with symptoms of hyperextensible
and abnormally fragile skin, as well as hyperextensibility
of articulations, was first described in humans in 1892
[1]. The name Ehlers-Danlos Syndrome (EDS) was pro-
posed in 1934 to describe this disease complex [2]. This
syndrome is caused by various mutations with different
modes of heredity and was categorized into different
subtypes because of variation in affection of blood ves-
sels, internal organs, wound healing and impact on the
pregnancy, additional to the typical lesions on skin and
joints [3-5].
EDS-like diseases have been described for decades in
cat [6], dog [7], rabbit [8], mink [7], cattle [9], sheep [10]
and horse [9,11], with variable heredity in the different
species. These syndromes were commonly described as
cutis hyperelastica, hyperelastosis cutis, dermatosparaxis,
dermal/collagen dysplasia, dermal/cutaneous asthenia or
Ehlers-Danlos-like syndrome/s [8,9,11-17].
« Ehlers-Danlos-like syndromes » (EDLS) will be used
in this paper to describe the syndromes in animals, in
which the clinical findings are similar to human EDS,
independent of their origin.
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In several cases of EDLS in different species, mutations
were detected in genes encoding for enzymes involved in
production of collagen or other components of the dermal
extracellular matrix [2,12,13,18-22].
In equines, EDLS are described in Draught horses
[14], Warmblood horses [9,15,23,24], Arabians [25],
Quarter Horses and Quarter lineage [16,26-37] as well
as Thoroughbreds [11]. These syndromes were described
in neonates, juveniles and adults. Two gene defects caus-
ing an EDLS phenotype in horses have been discovered in
recent years. Since 2007, the test for the well documented
hereditary equine regional dermal asthenia (HERDA) in
Quarter Horses and related breeds, testing for the known
PPIB:p.39Gly > Arg mutation of the peptidylprolyl isomer-
ase B (cyclophilin B) gene, is available [13,16,31-36,38].
For Warmblood Fragile Foal Syndrome Type 1 (WFFS),
a genetic test developed by N. Winand became commer-
cially available in 2013a [39]. This autosomal recessive
inherited disease occurs in Warmblood horses and related
breeds and is reportedly caused by a point mutation
(c.2032G >A, p.Gly678Arg) in the equine procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) gene [39].
PLOD1 is an important posttranslational modifying
enzyme in collagen biosynthesis, which hydroxylates
specific lysines in collagen [19]. These hydroxylysines act
as precursors for crosslinking that are responsible for the
tensile strength, mechanical stability of collagen fibrils and
are involved in the formation of fibers [4,19,21]. Plod1
knock-out mice are flaccid, have gait abnormalities and
about 15% of them die because of aortic rupture. Smooth
muscle cells in non-ruptured Plod1−/− aortas showed de-
generative changes and collagen fibrils in the Plod1−/−
aorta and skin showed abnormal morphology [40]. Over
20 different mutations have been reported for the human
PLOD1 gene and are associated with clinical Ehler-
Danlos-Syndrome type VI, also called the kyphoscoliotic
type, with the most common human mutation (25%) be-
ing a duplication of exons 10–16 [19-21,41]. Ten human
pathogenic variants were point mutations in different
exon regions of PLOD1, which were also shown to be as-
sociated with a decreased enzyme activity in Ehler-Danlos
Type VI patients [21]. Symptoms of this autosomal reces-
sive inherited connective tissue fragility syndrome occur
from birth on and are characterized by skin hypersen-
sibility, muscle hypotonia, joint laxity, eyes and vessels
involvement, scoliosis and premature rupture of fetal
membranes [3,4,18-21,41-43]. Life span of these patients
may be normal, but affected individuals are at risk for rup-
ture of medium sized arteries [4,19].
The decreased activity of PLOD1 leads to reduced
hydroxylysine-based pyridinoline cross-links in collagens
and therefore to an increased lysylpyridinoline (LP) to
hydroxylysylpyridinoline (HP) ratio in urine, which is
used to diagnose kyphoscoliotic EDS VI [4]. Another
method to test these patients for EDS, kyphoscoliotic
form, is the measurement of PLOD1 enzyme activity in
cultured fibroblasts [4,19].
Mutations in the PLOD1 gene were not described in
animals up to the patent application for the WFFS test
[39]. To our knowledge, this is the first case report de-
scribing the clinical and histopathological changes in a
genetically confirmed homozygous WFFS foal.
Case presentation
A 5-year-old Westfalian Warmblood mare was referred
to the Clinic of Reproductive Medicine for dystocia in
March 2012. During pregnancy, no complications were
detected and parturition occurred near the calculated
date of term. The obstetrical examination revealed a living
foal in cranial presentation, dorso-sacral position, with
bilateral carpal flexion. Correction of carpal flexion was
not possible in the standing mare, resulting in the decision
to perform a controlled vaginal delivery under general
anaesthesia. Ten minutes after induction of anaesthesia,
correction of bilateral carpal flexion was possible after
elevation of the mare’s hindquarters. A living filly was
extracted after solely manual correction with slight trac-
tion. The foal presented with an open abdomen and exten-
sive skin lesions (Figure 1). Obstetrical devices were not
used for the gentle correction and extraction procedure,
which makes idiopathic causes for the injuries unlikely.
The newborn was euthanized due to poor prognosis and a
full necropsy was performed. The mare was released from
the clinic in healthy condition after treatment for retained
foetal membranes.
Pathological findings
On macroscopic necropsy examination, the foal presented
with multiple extensive (up to 20 cm in length) and severe
skin lacerations on both front legs and face. The abdomen
was open on midline measuring approximately 30 cm in
length with eventration of the small intestines.
In the affected areas, the skin was extremely fragile
and thin (1 to 2 mm), friable and very loosely attached
to the underlying subcutaneous tissue (Figure 2). Pres-
sure points on head as well as front and hind limbs
showed subcutaneous oedema, hematomas and seromas,
particulary affected were the fetlocks and tarsus regions.
Several samples of lesional and non-lesional skin were
fixed in 10% neutral buffered formalin, paraffin-embedded,
sectioned at 3 μm, and stained with haematoxylin and
eosin (HE) for light microscopy. On histologic examin-
ation, the abnormally thin dermis showed a markedly
reduced amount of dermal collagen bundles that were
of variable thickness and orientation and loosely ar-
ranged with abnormally large spaces between deep der-
mal fibers. The epidermis and adnexal structures were
normal (Figure 3).
Monthoux et al. BMC Veterinary Research  (2015) 11:12 Page 2 of 8
Electron microscopy (EM) was performed on affected
skin samples from various locations of the body. For
negative contrast EM, selected tissues were fixed in 2.5%
glutaraldehyde and 1% osmium tetroxide (OsO4) and
buffered with 0.1 M sodium phosphate (pH 7.4). After
fixation, the tissues were dehydrated in an ethanol series,
embedded in Epoxy resinb, cut in ultrathin (90 nm) sec-
tions and stained with uranyl acetate and lead citrate.
EM examination revealed only mild abnormalities. The
collagen fibrils were reasonably well organised in bundles
forming parallel arrays and showed regular periodic band-
ing. However, mild randomness in orientation and mild
variability of the cross-sections of the collagen fibrils were
present (Figure 3).
Genetic tests
At the time of necropsy, the only available genetic test
for EDLS was the test for HERDA, for which the mare
was homozygous negative. In spring 2013, when the
WFFS-test became commercially availablea, the mare was
tested and resulted heterozygous positive for the WFFS al-
lele (A/G). The stallion was not tested. Consequently, for-
malin fixed muscle tissue of the foal was also submitted
for genetic testing. Genomic DNA was extracted from
muscle tissue using the commercially available MagNA
Pure 96 DNA and Viral NA Small Volume Kitc following
manufacturers’ instructions. Genotyping was performed
for the XM_001491331:c.2032G >A variant in the PLOD1
gene, which is supposed to be the causative variant for
Figure 1 Clinical presentation of the WFFS foal. The foal presented with severe ablation of skin on the right front leg (above) and an open
abdomen and eventration of the small intestines (below).
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Figure 2 Skin morphology of the WFFS foal. Affected skin from the front limb (above) is markedly thinner (<1.5 mm) than unaffected skin
from the back (below) of the same foal.
Figure 3 Light and electron microscopy of affected (a&c) and unaffected (b&d) skin. Light microscopy of affected (a) and unaffected (b)
skin: The deep dermis is markedly thinned (approximately 30% of dermal thickness of hind limb skin of unaffected 1-day-old control Warmblood
foal (b)) and shows a reduced number of thin, irregular collagen bundles separated by clear spaces. The epidermis and adnexal structures appear
normal. Subcutaneous tissue was detached from the overlying dermis and is missing on this slide. The size bars indicate 200 μm. Haematoxylin
and eosin staining (HE), 4x. Electron microscopy of affected (c) and unaffected (d) skin: In the affected skin (c) (front limb) a mild randomness in
orientation and variability of the cross-sections of the collagen fibrils are present. The size bar indicates 0.5 μm. The skin of the control (d) (hind
limb from a 1-day-old control Warmblood foal) shows regular orientation of collagen fibrils with no visible variability of cross-sections. The size
bar indicates 1 μm.
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Warmblood Fragile Foal Syndrome type 1 (WFFS) ac-
cording to the patent application [39] (primers and
PCR conditions available from Laboklin, Bad Kissingen,
Germany upon request). The results revealed a homozy-
gous positive WFFS (A/A) genotype for the foal. Close rel-
atives to the foal, all healthy, were also tested for the
WFFS genotype and revealed either a carrier genotype
(A/G; two tested half-sisters of the foal sired by the same
stallion) or a homozygous wild type genotype (G/G; two
mothers of the heterozygous half-sisters and the full sister
of the mother of the homozygous positive and symptom-
atic foal) (Figure 4). All samples for genetic analysis were
submitted to the laboratory without mentioning clinical
suspicion for WFFS. The Clinic of Reproductive Medicine
and the owner of the horses were fully charged for all
tests.
Discussion
Case reports about EDLS describing clinical, histological
and EM findings in horses were well recorded this past
decade, but usually without any genetic confirmation as
HERDA and WFFS tests were not available. Now, after
the discovery of two genetic causes, previous cases may
be explained by the newly detected mutations.
The majority of published EDLS case reports in horses
describe the clinical signs of HERDA mutation in the
Quarter Horse. Nevertheless, there are several EDLS
cases documented in other breeds than Warmblood or
Quarter horses [11,14,25]. These horses presented with
several of the following symptoms: skin hyperelasticity;
loss of the hoof capsule; lesions on the back, the flanks,
shoulders and legs; pathologic scar formation; and abor-
tion or embryonic loss in related pairings [11,14,25].
Literature of HERDA homozygous symptomatic horses,
after the launch of the genetic test in 2007 [13,31-33], en-
abled the description of a more precise phenotype for this
mutation: fragile and hyperextensible skin, lacerations,
seromas, haematomas, ulcerations and scars with typical
localisation on the dorsal region extending to other
parts of the body [16]. The disease may also affect other
tissues, such as tendons, ligaments, great vessels or the
cornea. These clinical signs most commonly emerge in
older horses; however, documentation of neonatal cases
exist [16].
Genetically confirmed WFFS cases were not available
in previous literature; however, four case reports of
EDLS clinical signs in Warmblood horses have been
reported [9,15,23,24]. The first two cases in neonates
(one and six days old) showed skin lesions on the
limbs, abdominal region, withers and underneath the
tail, with hyperextension of the limb articulations,
hydrops, subcutaneous emphysema, and a general modi-
fied integument [9,23]. In another case report, a 6-week-
old foal developed haematomas, multiple lacerations, scars
and oedema and displayed poor wound healing with skin
lesions localised on the flank, stifle and limb regions [15].
Regarding age (1.5 years) and localisation of lesions, the
last case is atypical. In this case, the horse displayed
wound-healing problems and dermatological modifica-
tions of the skin and hair on the flank and back. The dor-
sal skin, lateral to the thoracolumbar region, was
hyperelastic and painful [24]. Retrospectively, these four
Figure 4 Results of the genetic testing of the foal and close relatives. WFFS carriers in the relatives of the homozygous foal are the mare
(M) and two of his half-sisters (HS) from the same stallion (S). The mothers of the half-sisters (OM) and the mare’s half-sister (MHS) were
homozygous for the wild-type allele. The stallion was not tested for WFFS.
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clinical cases without association to a specific genotype
are now suspicious for WFFS. As suggested by Steelman
(2013), EDLS in horses seems to be a collection of similar
phenotypes with different genetic origin [36], so differenti-
ation between HERDA, WFFS and other EDLS cases is
difficult without genetic testing (Table 1).
Necropsy alone appears insufficient to diagnose one of
the EDLS types, as many similarities were observed in
the lesions of our positive tested WFFS case, the cases
retrospectively suspicious for WFFS and other docu-
mented EDLS cases. Additionally, it is unclear if other
atypical phenotypes exist for this disease. Perhaps the
birth of foals with cutaneous malformations is not the
only clinical presentation. In humans, EDS symptomatic
fetuses of asymptomatic mothers were affected by pre-
mature birth, still birth and abortion [18,42-47]. As the
foetal membranes find their origin in the embryo, the
connective tissue in these membranes may also be
affected and leading to their premature rupture, causing
the above described complications of pregnancy [44].
These clinical manifestations of cases with similar causa-
tive mechanism can lead to the suggestion that cases of
abortion, still birth and premature labour may also be
caused by WFFS, even when there are no case reports
available. Widespread genetic testing, especially of abor-
tions and symptomatic offspring of heterozygous (A/G)
pairings, will help to obtain a more detailed description
of the clinical signs that may be caused by this mutation.
Detailed information about the prevalence of the WFFS
mutation is not available in the literature. The human
EDSVI is rare with a disease incidence of approximately
1:100,000 live births and an estimated carrier frequency of
1:150 [19,20]. The patent application for the test describes
test results of 124 horses. The carrier frequency in the
tested clinically normal adult Warmblood population was
11.11%. Perfect association between homozygosity (A/A,
n = 2) and clinical WFFS symptoms was observed. Het-
erozygous (A/G, n = 8) and wild type homozygous (G/G,
n = 114) animals were all phenotypically normal. The car-
rier frequency in the initial test population was corrobo-
rated by the data of 500 randomly selected Warmblood
horses in Germany, where 9.5% of the population were
detected as carriers (Personal Communication: Gunreben
B.a; 2013). The seven horses tested for this case report
reflect these results with regard to association between
genotype and phenotype: a clinical phenotype was observed
solely in the homozygous positive foal. Up to now, no re-
ports are available for genetically confirmed homozygous
Table 1 Synoptical table for congenital skin lesions and malformations in horses
Disease WFFS HERDA EDLS
Full Name Warmblood Fragile Foal Syndrome Hereditary Equine Regional Dermal
Asthenia
Ehlers-Danlos-like syndrome of
unknown origin
Breed Warmblood Quarter Horse (lineage: stallion
Poco Bueno)
Warmblood, Quarter horse, Drafthorse,
Arabian, Thoroughbred
Gene PLOD1: “procollagen-lysine,
2-oxoglutarate 5-dioxygenase
1” (LH1: lysyl hydrohylase 1)
PPIB: “peptidyl-prolyl cis-trans
isomerase B”
(Cyclophilin B)
Involved genes not elucidated up to
now
Symptoms Lesions of skin/mucosa (tearing,
ulcerations); Hyperextension
of articulations,
floppy ears, hydrops,
subcutaneous emphysema,
hematomas, premature birth
Fragile and hyper extensible skin,
lacerations, seromas, hematomas,
ulcerations, scars
Skin hyper elasticity, loss of hoof
capsule, lesions on back, flanks,
shoulders, legs, scarring, pregnancy
loss, retention of fetal membranes
Localisation of lesions Head, neck, thorax, legs, abdomen,
stifle, withers, perineum, oral mucous
membranes, articular cartilage
Back and from back extending, may
involve: tendons, ligaments, great
vessels, cornea
Variable
Age Most common in neonates Mostly older horses, also possible
in neonates
Neonates as well as adult horses
Heredity Autosomal recessive Autosomal recessive Heredity mode not described
Genetic testing available Yes Yes No
Prevalence of mutation Up to 11.11% in clinically normal
adult Warmblood horses
Prevalence up to 28.3% in Cutting horses Prevalence unknown
Data sources Patent application Ishikawa et al. (2012) [13] Gunson et al. (1984) [25]
Winand N (2012) Mochal et al. (2010) [33] Esser M. et al. (1999) [19]
Grady et al. (2009) [32] Solomons B (1984) [11],
Rufenacht S et al. (2010) [24]
Steelman et al. (2013) [36]
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positive animals for the WFFS mutation with absence of
clinical symptoms.
Conclusions
Due to the severe clinical signs, this novel genetic disease
requires further investigation to obtain robust data on
prevalence of the mutation as well as the correlation be-
tween genotype and phenotype. Homozygous (A/A) off-
spring can be avoided from now on easily by breeding
heterozygous carriers only to homozygous negative breed-
ing partners. Awareness for this new disease will hopefully
result in the genetic testing of suspicious cases as identifi-
cation of homozygous animals provides the unique oppor-
tunity to study the biochemical and clinical consequences
of the mutation to obtain an in-depth characterization of
WFFS.
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